Breaking News Instant updates and real-time market news.

TDOC

Teladoc

$55.60

1.91 (3.56%)

, CVS

CVS Health

$53.90

0.54 (1.01%)

05:22
04/01/19
04/01
05:22
04/01/19
05:22

Teladoc oversold on Aetna contract confusion, says Piper Jaffray

Piper Jaffray analyst Sean Wieland believes some confusion over Aetna's intentions have pressured the shares of Teladoc (TDOC). The confusion lies in the fact that this was a "Request for Price" and not a "Request for Proposal," Wieland tells investors in a research note. However, his channel checks indicate there isn't any intention of CVS Health's (CVS) Aetna switching vendors. To the contrary, we've seen companies do this in front of a contract expansion, when they need to provide the board with benchmark pricing data to prove they are not overpaying, says the analyst. As such, he believes potential risk related to Teladoc's Aetna contract is minimal. Further, Wieland sees upside to Teladoc's initial guidance on stronger utilization trends as "telemedicine continues to go mainstream." He views the stock as oversold and reiterates an Overweight rating with an $86 price target.

TDOC

Teladoc

$55.60

1.91 (3.56%)

CVS

CVS Health

$53.90

0.54 (1.01%)

  • 05

    Jun

TDOC Teladoc
$55.60

1.91 (3.56%)

02/28/19
ADAM
02/28/19
NO CHANGE
Target $95
ADAM
Buy
Teladoc weakness a buying opportunity, says Canaccord
Canaccord analyst Richard Close said the weakness in Teladoc following Q4 results is a buying opportunity. He believes the company reined in the aggressive Street estimates and that guidance is likely conservative. Close reiterated his Buy rating and raised his price target to $95 from $94 on Teladoc shares.
03/04/19
RHCO
03/04/19
NO CHANGE
Target $75
RHCO
Buy
Teladoc price target raised to $75 from $70 at SunTrust
SunTrust analyst Sandy Draper raised his price target on Teladoc to $75 and kept his Buy rating, saying the review of his financial model and conversations with the company management suggest that its FY19 guidance has been set too conservatively. The analyst believes that Teladoc's two key metrics - paying members and utilization - will exceed his prior expectations and also offers a more positive outlook on the "wide-scale telehealth adoption" given the company's "strong sales pipeline and an increasingly more favorable legislative environment."
03/27/19
JPMS
03/27/19
NO CHANGE
JPMS
Teladoc recent selloff a buying opportunity, says JPMorgan
JPMorgan analyst Lisa Gill says the recent pullback in shares of Teladoc presents a buying opportunity.
03/28/19
JPMS
03/28/19
NO CHANGE
Target $80
JPMS
Overweight
Teladoc 19% selloff presents buying opportunity, says JPMorgan
JPMorgan analyst Lisa Gill views the 19% pullback since March 21 in shares of Teladoc as a buying opportunity. The analyst does not have a fundamental reason to point to for the selloff and believes the company's underlying fundamentals are unchanged. Gill has heard some concerns following the Forbes article earlier this week that questioned Teladoc's use of an adjusted EBITDA metric. She notes, however, that nearly all of the companies within her coverage universe focus investors on an adjusted EBITDA or adjusted EBIT. With the acquisitions that Teladoc has done over the past few years, amortization has grown significantly, and excluding that helps to better understand the underlying growth of the business, Gill tells investors in a research note. The analyst continues to see "significant runway" in the telehealth space going forward and keeps an Overweight rating on Teladoc with an $80 price target.
CVS CVS Health
$53.90

0.54 (1.01%)

03/13/19
03/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Outperform at Bernstein. 2. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at Ladenburg. 3. Solaris Oilfield (SOI) initiated with a Buy at B. Riley FBR. 4. Americold Realty Trust (COLD) initiated with a Buy at Berenberg. 5. Cheniere Energy (LNG) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
03/27/19
WELS
03/27/19
NO CHANGE
WELS
Centene might internalize WellCare PBM business, says Wells Fargo
Wells Fargo analyst Peter Costa notes that Centene (CNC) announced plans to acquire WellCare (WCG) for $120 in cash and 3.38 shares of Centene for each share of WellCare. The analyst expects Centene to eventually internalize WellCare's pharmacy benefit management (PBM) business, which would likely be another blow to CVS (CVS), WellCare's current PBM. Centene currently has some of its PBM business with CVS and is bringing that business in-house to its own internal PBM, while WellCare is planning to rebid its PBM contract this year, he notes, adding that this merger would likely mean that contract rebid may not occur and that WellCare would more likely move its estimated $15B-$20B in pharmacy spend away from CVS to Centene for 2021.
03/28/19
GSCO
03/28/19
NO CHANGE
GSCO
Federal judge blocking Medicaid work rule positive for MCOs, says Goldman Sachs
Goldman Sachs analyst Stephen Tanal noted that Politico reported that a federal judge ruled for the second time to block new work requirements as a condition for Medicaid eligibility in Kentucky and Arkansas, calling the ruling an incremental positive for Managed Care and Provider companies. MCOs whose primary business is Medicaid managed care are most exposed to this theme, said Tanal, who lists Molina (MOH), WellCare (WCG) and Centene (CNC) as three with a higher percentage of MMC lives in states that have submitted waivers requesting approval to impose work requirements. However, the analyst also noted that Kentucky's Governor has already issued an executive order indicating the state would appeal any decision by a court against work requirements and, if unsuccessful, would reverse its Medicaid Expansion program. WellCare, CVS' (CVS) Aetan, Humana (HUM) and Anthem (ANTM) all operate in Kentucky's Medicaid managed care program, the analyst noted.

TODAY'S FREE FLY STORIES

TELL

Tellurian

$9.04

0.75 (9.05%)

13:25
08/22/19
08/22
13:25
08/22/19
13:25
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/22/19
08/22
13:25
08/22/19
13:25
General news
Treasury's $7 B 30-year TIPS reopening was well received »

Treasury's $7 B…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Total Amount data reported »

30-Yr TIPS Auction Total…

NTRA

Natera

$30.66

0.25 (0.82%)

13:18
08/22/19
08/22
13:18
08/22/19
13:18
Hot Stocks
Natera reports 'positive' local coverage determination issued by Palmetto MolDX »

Natera announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/22/19
08/22
13:17
08/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/22/19
08/22
13:16
08/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/22/19
08/22
13:15
08/22/19
13:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NTRA

Natera

$30.53

0.12 (0.39%)

13:13
08/22/19
08/22
13:13
08/22/19
13:13
Recommendations
Natera analyst commentary  »

Piper says Natera gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

13:10
08/22/19
08/22
13:10
08/22/19
13:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD peaked…

AMGN

Amgen

$204.16

0.32 (0.16%)

13:06
08/22/19
08/22
13:06
08/22/19
13:06
Hot Stocks
Amgen granted orphan designation for multiple myeloma treatment »

Amgen was granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

ZIOP

Ziopharm

$5.09

-0.06 (-1.17%)

13:05
08/22/19
08/22
13:05
08/22/19
13:05
Options
Ziopharm call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

SNY

Sanofi

$42.69

-0.48 (-1.11%)

13:04
08/22/19
08/22
13:04
08/22/19
13:04
Hot Stocks
Sanofi treatment of systemic sclerosis granted orphan designation »

Sanofi U.S. Service was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 02

    Oct

WFC

Wells Fargo

$45.62

0.63 (1.40%)

13:03
08/22/19
08/22
13:03
08/22/19
13:03
Periodicals
Wells Fargo to pay $6.5M to Navajo Nation to settle account suit, Reuters says »

Wells Fargo intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

ILMN

Illumina

$288.00

-2.5 (-0.86%)

13:02
08/22/19
08/22
13:02
08/22/19
13:02
Hot Stocks
Illumina granted orphan designation neuroblastoma management diagnostic »

Illumina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

OSTK

Overstock.com

$21.84

2.34 (12.00%)

12:49
08/22/19
08/22
12:49
08/22/19
12:49
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$21.40

1.9 (9.74%)

12:45
08/22/19
08/22
12:45
08/22/19
12:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.13

-0.71 (-0.35%)

, ALXN

Alexion

$118.04

3.17 (2.76%)

12:43
08/22/19
08/22
12:43
08/22/19
12:43
Recommendations
Amgen, Alexion analyst commentary at Piper Jaffray »

Piper Jaffray says Amgen…

AMGN

Amgen

$203.13

-0.71 (-0.35%)

ALXN

Alexion

$118.04

3.17 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

12:40
08/22/19
08/22
12:40
08/22/19
12:40
General news
Fed funds futures are lower after the hawkish comments »

Fed funds futures are…

ADM

Archer Daniels

$37.93

0.23 (0.61%)

, REGI

Renewable Energy

$11.27

0.42 (3.87%)

12:38
08/22/19
08/22
12:38
08/22/19
12:38
Periodicals
Trump to discuss biofuels with USDA, EPA officials, Reuters reports »

President Donald Trump is…

ADM

Archer Daniels

$37.93

0.23 (0.61%)

REGI

Renewable Energy

$11.27

0.42 (3.87%)

GPRE

Green Plains

$8.03

0.15 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

OSTK

Overstock.com

$19.54

0.04 (0.21%)

12:33
08/22/19
08/22
12:33
08/22/19
12:33
Hot Stocks
Byrne says Overstock's blockchain keiretsu will revolutionize the world »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$19.54

0.04 (0.21%)

12:30
08/22/19
08/22
12:30
08/22/19
12:30
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.12

-0.28 (-0.10%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
08/22/19
08/22
12:29
08/22/19
12:29
General News
Canada still against Russia's return to G8, Reuters says »

Canada's government…

SPY

SPDR S&P 500 ETF Trust

$292.12

-0.28 (-0.10%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.07

-0.335 (-0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:28
08/22/19
08/22
12:28
08/22/19
12:28
General News
Ukraine, EU rebuff Trump's suggestion of admitting Russia to G7, Reuters says »

Ukraine's President…

SPY

SPDR S&P 500 ETF Trust

$292.07

-0.335 (-0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

-2.27 (-1.24%)

, SNAP

Snap

$16.24

0.1 (0.62%)

12:27
08/22/19
08/22
12:27
08/22/19
12:27
Periodicals
Gun sellers allegedly used Snapchat to sell illegal guns, Guardian says »

Darwin BondGraham, a…

FB

Facebook

$181.29

-2.27 (-1.24%)

SNAP

Snap

$16.24

0.1 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.